Monopar Therapeutics Inc - ESG Rating & Company Profile powered by AI
The ESG score for Monopar Therapeutics Inc represents the company's transparency towards the UN SDGs. This analysis of Monopar Therapeutics Inc uses information from across the internet as well as from public filings by Monopar Therapeutics Inc. This page displays a free E,S&G assessment for Monopar Therapeutics Inc.
Monopar Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.7; made up of an environmental score of 8.0, social score of 3.2 and governance score of 6.0.
5.7
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
541 | Wntresearch AB | 5.8 | High |
541 | Zenotech Laboratories Ltd | 5.8 | High |
579 | Monopar Therapeutics Inc | 5.7 | High |
579 | Caplin Point Laboratories Ltd | 5.7 | High |
579 | Biotest AG | 5.7 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Monopar Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Does Monopar Therapeutics Inc disclose current and historical energy intensity?
Does Monopar Therapeutics Inc report the average age of the workforce?
Does Monopar Therapeutics Inc reference operational or capital allocation in relation to climate change?
Does Monopar Therapeutics Inc disclose its ethnicity pay gap?
Does Monopar Therapeutics Inc disclose cybersecurity risks?
Does Monopar Therapeutics Inc offer flexible work?
Does Monopar Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Monopar Therapeutics Inc disclose the number of employees in R&D functions?
Does Monopar Therapeutics Inc conduct supply chain audits?
Does Monopar Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Monopar Therapeutics Inc conduct 360 degree staff reviews?
Does Monopar Therapeutics Inc disclose the individual responsible for D&I?
Does Monopar Therapeutics Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Monopar Therapeutics Inc disclose current and / or historical scope 2 emissions?
Does Monopar Therapeutics Inc disclose water use targets?
Does Monopar Therapeutics Inc have careers partnerships with academic institutions?
Did Monopar Therapeutics Inc have a product recall in the last two years?
Does Monopar Therapeutics Inc disclose incidents of discrimination?
Does Monopar Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Has Monopar Therapeutics Inc issued a profit warning in the past 24 months?
Does Monopar Therapeutics Inc disclose parental leave metrics?
Does Monopar Therapeutics Inc disclose climate scenario or pathway analysis?
Does Monopar Therapeutics Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Monopar Therapeutics Inc disclose the pay ratio of women to men?
Does Monopar Therapeutics Inc support suppliers with sustainability related research and development?
Does Monopar Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Monopar Therapeutics Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Monopar Therapeutics Inc involved in embryonic stem cell research?
Does Monopar Therapeutics Inc disclose GHG and Air Emissions intensity?
Does Monopar Therapeutics Inc disclose its waste policy?
Does Monopar Therapeutics Inc report according to TCFD requirements?
Does Monopar Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Monopar Therapeutics Inc disclose energy use targets?
Does Monopar Therapeutics Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Monopar Therapeutics Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Monopar Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.